Create Account | Sign In: Author or Forum

 
News  |  Journals  |  Conferences  |  Opinion  |  Articles  |  Forums  |  Twitter    
 
Category: Cardiology | Gynecology | Internal Medicine | Nursing | Oncology | Pharmacy | Journal

Back to Journal Articles

Anthracycline, Trastuzumab for Breast CA Up Heart Failure Risk

Last Updated: September 05, 2012.

 

Risk of heart failure and/or cardiomyopathy up for women with incident, invasive breast cancer

Share |

Comments: (0)

Tell-a-Friend

 

  Related
 
For women with incident, invasive breast cancer, treatment with anthracycline and trastuzumab is associated with an increased risk of heart failure and/or cardiomyopathy, compared to having no chemotherapy, according to a study published in the Sept. 5 issue of the Journal of the National Cancer Institute.

WEDNESDAY, Sept. 5 (HealthDay News) -- For women with incident, invasive breast cancer, treatment with anthracycline and trastuzumab is associated with an increased risk of heart failure and/or cardiomyopathy, compared to having no chemotherapy, according to a study published in the Sept. 5 issue of the Journal of the National Cancer Institute.

To estimate the association between anthracycline and trastuzumab use and incident heart failure and/or cardiomyopathy, Erin J. Aiello Bowles, M.P.H., from the Group Health Research Institute in Seattle, and colleagues retrospectively analyzed data from a cohort of 12,500 women (mean age, 60 years) diagnosed with incident, invasive breast cancer from Jan. 1, 1999, to Dec. 31, 2007. Procedure and pharmacy codes were used to identify chemotherapy use.

The researchers found that 29.6 percent of participants received anthracycline alone, 0.9 percent received trastuzumab alone, 3.5 percent received both anthracycline and trastuzumab, 19.5 percent received other chemotherapy, and 46.5 percent received no chemotherapy. Compared with recipients of other chemotherapy or no chemotherapy, recipients of anthracycline and trastuzumab were younger, with fewer comorbidities. The risk of heart failure and/or cardiomyopathy was increased for patients treated with anthracycline alone (adjusted hazard ratio [aHR], 1.40), compared to no chemotherapy, and was similar to the risk seen for patients treated with other chemotherapy (aHR, 1.49). Patients treated with trastuzumab alone or anthracycline plus trastuzumab had a highly increased risk (aHR, 4.12 and 7.19, respectively).

"Anthracycline and trastuzumab were primarily used in younger, healthier women and associated with increased heart failure and/or cardiomyopathy risk compared with no chemotherapy," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text
Editorial

Copyright © 2012 HealthDay. All rights reserved.


Previous: Over Half of U.S. Adults With HTN Do Not Have It Under Control Next: Quitting Smoking Cuts Elevated Subarachnoid Hemorrhage Risk

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion:

Name:

Email:

Location:

URL:

Remember my personal information

Notify me of follow-up comments?

advertisement.gif (61x7 -- 0 bytes)
 

Are you a Doctor, Pharmacist, PA or a Nurse?

Join the Doctors Lounge online medical community

  • Editorial activities: Publish, peer review, edit online articles.

Doctors Lounge Membership Application

 
     

 advertisement.gif (61x7 -- 0 bytes)

 

 

Useful Sites
MediLexicon
  Tools & Services: Follow DoctorsLounge on Twitter Follow us on Twitter | RSS News | Newsletter | Contact us
Copyright © 2001-2014
Doctors Lounge.
All rights reserved.

Medical Reference:
Diseases | Symptoms
Drugs | Labs | Procedures
Software | Tutorials

Advertising
Links | Humor
Forum Archive
CME | Conferences

Privacy Statement
Terms & Conditions
Editorial Board
About us | Email

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.